Clinical trials: Adult Attention Deficit Hyperactivity Disorder
- Condition Adult Attention Deficit Hyperactivity Disorder
- Funder type Industry (pharma, biotech, devices)
Attention Deficit Hyperactivity Disorder
Predictive Executive Functioning Models Using Interactive Tangible-Graphical Interface Devices in Adults
Current diagnostic aids used in treating ADHD are currently expensive, time intensive, and provide little information about accessory movements in response to a stimulus.
- Trial name
- NCT02127931
- Testing
- Groundskeeper for ADHD group, Groundskeeper for control group
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- CogCubed, Corp
Attention Deficit Hyperactivity Disorder
Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate
The purpose of the AR19.004 study is to assess the efficacy of AR19 compared to placebo using the Adult ADHD Investigator Symptom Rating Scale (AISRS)
- Trial name
- NCT03659929
- Testing
- Amphetamine Sulfate
- Where
- 31 sites in United States
- Volunteers
- 320 people
- Sponsor
- Arbor Pharmaceuticals, Inc.
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder
This study evaluated the efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with ADHD. Participants either received a twice-daily dose of centanafadine sustained-release tablets, or…
- Trial name
- NCT03605836
- Testing
- Centanafadine SR
- Where
- United States
- Volunteers
- 590 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Hyperactivity Disorder (ADHD)
PRC-063 in an ADULT Workplace Environment
The primary objective of this study is to assess the time of onset and time course of efficacy over 16 hours of PRC-063 compared to placebo in adults diagnosed with ADHD in a simulated adult workplace environment (AWE) setting…
- Trial name
- NCT02225639
- Testing
- PRC-063 25 mg, PRC-063 35 mg, PRC-063 45 mg
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
Attention-Deficit Hyperactivity Disorder
Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
To evaluate the sensitivity and responsiveness of a standardized, validated, computer-based, battery of neuro-psychometric tests in adults with ADHD.
- Trial name
- NCT01010750
- Testing
- Lisdexamfetamine Dimesylate (LDX), Immediate Release Mixed Amphetamine Salts (MAS-IR)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Shire
Attention Deficit Disorder With Hyperactivity
Effects of Using Betahistine to Treat Adults With Attention Deficit Hyperactivity Disorder
This study will determine whether the drug betahistine increases focus and causes side effects in people with attention deficit hyperactivity disorder.
- Trial name
- NCT00829881
- Testing
- Betahistine Hydrochloride
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- P2D, Inc.
Attention Deficit Hyperactivity Disorder
A Study to Test Different Ways to Measure the Effect of Atomoxetine on Impulsive Behavior in Young Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The primary objectives are to investigate the effect of atomoxetine on impulsivity after single dose and at steady state measured by the total score of Barrett Impulsiveness Scale version 11 (BIS-11) and Short Urgency…
- Trial name
- NCT05278104
- Testing
- Zentiva®
- Where
- 5 sites in Germany
- Volunteers
- 63 people
- Sponsor
- Boehringer Ingelheim
Attention-deficit/Hyperactivity Disorder, Emotional Dysregulation
A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
The primary purpose of this study is to evaluate the efficacy of centanafadine once daily (QD) extended-release (XR) capsules in adults with attention-deficit/hyperactivity disorder (ADHD) and emotional dysregulation (ED).
- Trial name
- NCT07759154
- Testing
- Centanafadine XR
- Where
- 16 sites in United States
- Volunteers
- 80 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Adult ADHD
Study to Investigate the Efficacy and Tolerability of AZD1446 in Adult ADHD Patients.
The purpose of this study is to determine whether 2 weeks of treatment with AZD1446 compared to placebo improves ADHD symptoms and is well tolerated.
- Trial name
- NCT01012375
- Testing
- AZD1446
- Where
- 6 sites in United States
- Volunteers
- 135 people
- Sponsor
- AstraZeneca
Attention Deficit Hyperactivity Disorder, Comorbid Social Anxiety Disorder
Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder
To investigate the effect of atomoxetine hydrochloride in treating adults who have attention deficit hyperactivity disorder with comorbid social anxiety disorder
- Trial name
- NCT00190879
- Testing
- Atomoxetine hydrochloride
- Where
- 21 sites in United States, Puerto Rico
- Volunteers
- 440 people
- Sponsor
- Eli Lilly and Company
Attention-Deficit/Hyperactivity Disorder, ADHD
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
The safety and efficacy of multiple dosages of TD-9855, administered once daily, will be evaluated in adult males with ADHD.
- Trial name
- NCT01458340
- Testing
- TD-9855
- Where
- 17 sites in United States
- Volunteers
- 295 people
- Sponsor
- Theravance Biopharma
Attention-Deficit/Hyperactivity Disorder
Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
The objective of this study is to evaluate the long-term effects and tolerability of ABT-089 in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT00686933
- Testing
- ABT-089
- Where
- 12 sites in United States
- Volunteers
- 117 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Attention-Deficit/Hyperactivity Disorder
Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to investigate the treatment effectiveness of Adhansia XR at month-2 after initiation, and the effectiveness of Adhansia XR overall and when compared with the active comparator group (Concerta) over…
- Trial name
- RE-DAX (NCT04507204)
- Testing
- Adhansia XR, Concerta
- Where
- 35 sites in United States
- Volunteers
- 267 people
- Sponsor
- Purdue Pharma LP
ADHD
Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)
The goal of this clinical trial is to evaluate the efficacy and safety of NRCT-101SR compared to placebo in adult patients with ADHD aged 18 years and older.
- Trial name
- NCT05683249
- Testing
- NRCT-101-SR
- Where
- 9 sites in United States
- Volunteers
- 223 people
- Sponsor
- Neurocentria, Inc.
ADHD
A Trial to Assess How Centanafadine Interacts With Stimulants in the Body
This study will look at how centanafadine works when taken together with stimulant medicines in healthy adults, and whether combining them affects how the body responds.
- Trial name
- NCT07314333
- Testing
- Centanafadine, Methylphenidate, Lisdexamfetamine
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Hyperactivity Disorder
Atomoxetine Phase 2 Study in Japanese Adult Patients With Attention Deficit/Hyperactivity Disorder (ADHD)
The objective is to assess overall safety and tolerability of atomoxetine in doses up to 120 mg/day in Japanese adult patients who meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for…
- Trial name
- NCT00530335
- Testing
- Atomoxetine
- Where
- 12 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Investigating the Effect of Vortioxetine in Adult ADHD Patients
The purpose is to determine the effect of vortioxetine treatment on ADHD symptoms in adult patients with ADHD in a 12 weeks study.
- Trial name
- NCT02327013
- Testing
- vortioxetine 10 mg tablet, vortioxetine 20 mg tablet
- Where
- 15 sites in United States
- Volunteers
- 227 people
- Sponsor
- H. Lundbeck A/S
Attention Deficit/Hyperactivity Disorder
Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)
This study will evaluate efficacy and safety of methylphenidate hydrochloride extended release compared to placebo in adult patients with childhood-onset attention deficit/hyperactivity disorder (ADHD).
- Trial name
- NCT01259492
- Testing
- Ritalin LA 20 mg, Ritalin LA 30 mg
- Where
- 68 sites in United States, Belgium and 7 more
- Volunteers
- 725 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Adult Participants
Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects
The purpose of this study is to demonstrate dose strength equivalence of 2 × 164.4 milligrams (mg) centanafadine (CTN) once daily (QD) extended-release (XR) capsules to a 1 × 328.8 mg centanafadine QD XR capsule in healthy adult…
- Trial name
- NCT07486895
- Testing
- Centanafadine
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Hyperactivity Disorder, ADHD
Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With ADHD
The purpose of the study is to evaluate the efficacy and safety of modafinil administered once daily for 9 weeks at doses of 255, 340, 425, and 510 mg as treatment for adults with ADHD.
- Trial name
- NCT00315276
- Testing
- Modafinil
- Where
- 18 sites in United States
- Volunteers
- 370 people
- Sponsor
- Cephalon